The Smart Nebuliser FOX Wins Red Dot Design Award
Vectura Group plc announces that the smart nebuliser device FOX has won the 2014 Red Dot Award for product design.
The award winning FOX inhaler is a smart and efficient handheld nebuliser for treatment of respiratory diseases. Its breathing control enables highly accurate drug delivery to the small airways.
The FOX inhalation system is a hand-held, self-contained, battery-powered, mesh nebuliser device with high performance using Activaero's* own vibrating mesh aerosol generator. The mesh-based aerosolisation engine used in FOX is proprietary to Activaero*, the rights having been in-licensed to Activaero* on an exclusive basis from a third party. The FOX inhalation system also makes use of a flow sensing/controlling valve system and is both re-chargeable and Bluetooth-enabled. The latter feature allows for remote firmware updates without cable connection or for the system to upload patient use data for review by a healthcare professional.
The clear and user centric design of FOX make inhalation treatments potentially shorter in duration and more convenient.
Bernhard Müllinger, Chief Technical Officer at Vectura GmbH states "During the design process of FOX we undertook extensive market research to understand a device that patients use intuitively in the right way. Since most dose delivery errors associated with respiratory therapies are caused by inappropriate breathing patterns, we developed a LED lighting to prompt users to breathe correctly during dose administration. The device also features key-lock indicators for intuitive assembly of the components." FOX is fully battery powered and can be recharged with standard phone chargers with micro-USB connectors. Patients who use the FOX device can use the device at home, during work or while traveling.
Red Dot CEO and founder Dr Peter Zec, notes: "Our experts assessed the quality of the entries with the utmost care and attention…But only the best products receive an award from the jury. This is especially reflected in the percentage of successful entries in the Red Dot Award, which is much smaller in contrast to other international design competitions. Therefore, the winners can be proud of their achievements - with their entries, they stood out from the rest and were able to pass the test in front of the critical eyes of the experts."
Design winners are celebrated during a presentation at the acclaimed Red Dot Gala on 7 July 2014. The award-winning products will be displayed in a special exhibition at the Red Dot Design Museum in Essen, Germany from 8 July to 3 August 2014.
* Vectura GmbH (formerly Activaero GmbH) is a wholly owned subsidiary of Vectura Group plc
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance